CA2441744C - Formulations containing propofol and a sulfoalkyl ether cyclodextrin - Google Patents

Formulations containing propofol and a sulfoalkyl ether cyclodextrin Download PDF

Info

Publication number
CA2441744C
CA2441744C CA2441744A CA2441744A CA2441744C CA 2441744 C CA2441744 C CA 2441744C CA 2441744 A CA2441744 A CA 2441744A CA 2441744 A CA2441744 A CA 2441744A CA 2441744 C CA2441744 C CA 2441744C
Authority
CA
Canada
Prior art keywords
formulation
propofol
agent
sae
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2441744A
Other languages
English (en)
French (fr)
Other versions
CA2441744A1 (en
Inventor
Gerold L. Mosher
Diane O. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cydex Pharmaceuticals Inc
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Publication of CA2441744A1 publication Critical patent/CA2441744A1/en
Application granted granted Critical
Publication of CA2441744C publication Critical patent/CA2441744C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA2441744A 2001-03-20 2002-03-19 Formulations containing propofol and a sulfoalkyl ether cyclodextrin Expired - Lifetime CA2441744C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27730501P 2001-03-20 2001-03-20
US60/277,305 2001-03-20
PCT/US2002/008596 WO2002074200A1 (en) 2001-03-20 2002-03-19 Formulations containing propofol and a sulfoalkyl ether cyclodextrin

Publications (2)

Publication Number Publication Date
CA2441744A1 CA2441744A1 (en) 2002-09-26
CA2441744C true CA2441744C (en) 2011-07-12

Family

ID=23060281

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2441744A Expired - Lifetime CA2441744C (en) 2001-03-20 2002-03-19 Formulations containing propofol and a sulfoalkyl ether cyclodextrin

Country Status (6)

Country Link
US (1) US20030055023A1 (enExample)
EP (1) EP1383445A4 (enExample)
JP (1) JP4334229B2 (enExample)
AU (1) AU2002254309B2 (enExample)
CA (1) CA2441744C (enExample)
WO (1) WO2002074200A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
WO2003063824A2 (en) * 2002-02-01 2003-08-07 Shimoda Biotech (Pty) Ltd Pharmaceutical composition
HRP20050182A2 (en) 2002-07-29 2006-11-30 Transform Pharmaceuticals Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
US7089927B2 (en) * 2002-10-23 2006-08-15 New York University System and method for guidance of anesthesia, analgesia and amnesia
MXPA05002561A (es) * 2002-10-25 2005-05-05 Pfizer Prod Inc Nuevas formulaciones de liberacion prolongada inyectables.
PL375603A1 (en) * 2002-10-25 2005-12-12 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
WO2004039326A2 (en) * 2002-10-29 2004-05-13 Transform Pharmaceuticals, Inc. Propofol with cysteine
MXPA03009945A (es) 2002-11-05 2007-04-16 Lg Electronics Inc Montaje para montar una pantalla de toque para un monitor con pantalla de cristal liquido.
WO2004108113A1 (en) * 2003-06-10 2004-12-16 Dinesh Shantilal Patel Improved novel, clear, painless preparation of propofol
AR046769A1 (es) * 2003-12-22 2005-12-21 Schering Corp Composiciones farmaceuticas
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
JPWO2005067905A1 (ja) * 2004-01-14 2007-12-27 株式会社大塚製薬工場 プロポフォール含有脂肪乳剤
EP1713504B1 (en) * 2004-01-30 2017-06-07 Zoetis Services LLC Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
BRPI0510119A (pt) 2004-04-23 2007-09-25 Cydex Inc formulação para dpi contendo sulfoaquil éter de ciclodextrina
KR20070058608A (ko) * 2004-09-13 2007-06-08 바라트 쎄럼스 앤드 백신스 리미티드 항미생물 방부 효능을 갖는 정맥 내 투여를 위한 안정한에멀젼 조성물
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
WO2006112276A1 (ja) 2005-04-13 2006-10-26 Otsuka Pharmaceutical Factory, Inc. プロポフォール含有脂肪乳剤
JP2009504634A (ja) * 2005-08-12 2009-02-05 ブハラット セルムズ アンド ヴァクシンズ リミテッド プロポフォールを含む水性麻酔剤組成物
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
JP5537033B2 (ja) * 2005-12-19 2014-07-02 ザ ユニヴァーシティー オブ リヴァプール 無痛覚
JP2009520827A (ja) * 2005-12-20 2009-05-28 ティカ レーケメデル アーベー 肺内沈着の増大を有するコルチコステロイドを送達するためのシステムおよび方法
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
KR20100017435A (ko) * 2007-05-09 2010-02-16 파마코포어, 인크. 치료 화합물
EP2810927A1 (en) * 2007-05-09 2014-12-10 Sowood Healthcare LLC Therapeutic compounds
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
EP3210976A1 (en) 2008-03-31 2017-08-30 The General Hospital Corporation Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties
EP2106786A1 (de) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
NZ593345A (en) * 2008-11-15 2013-04-26 Rib X Pharmaceuticals Inc Antimicrobial composition comprising a quinolone carboxylic acid derivative and a cyclodextrin
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
AU2010234916A1 (en) * 2009-03-30 2011-10-13 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
BR112012000606A2 (pt) 2009-07-10 2016-11-22 Brigham & Womens Hospital análogos de etomidato que não inibem a síntese de esteróides adrenocorticais
CA2786762C (en) * 2010-01-21 2017-12-05 Goodchild Investments Pty Ltd Anaesthetic formulation
ES2882806T3 (es) * 2011-02-02 2021-12-02 Nestle Sa Composiciones nutricionales ricas en proteínas y métodos de fabricación y utilización de las mismas
DK2484350T3 (en) * 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
SI2802325T1 (sl) 2012-01-13 2017-04-26 The General Hospital Corporation Anestetične spojine in pripadajoči postopki za uporabo
PT3702374T (pt) 2012-02-15 2022-06-23 Cydex Pharmaceuticals Inc Processo de fabrico para derivados de ciclodextrina
CN110066351B (zh) 2012-02-28 2022-06-14 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法
KR101889121B1 (ko) * 2012-03-01 2018-09-20 노르베르트 뢰베르 제약 제제
CA2867121C (en) * 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AU2013326538B2 (en) * 2012-10-04 2017-09-14 Fresenius Kabi Austria Gmbh Application arrangement with a medicinal substance fluid
JP6557144B2 (ja) 2012-10-22 2019-08-07 サイデックス・ファーマシューティカルズ・インコーポレイテッド アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
WO2014075935A1 (de) 2012-11-15 2014-05-22 Sapiotec Gmbh Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff
KR102164174B1 (ko) 2012-12-11 2020-10-12 자피오텍 게엠베하 흑색종 세포를 퇴치하기 위한 델피니딘
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi
JP6392883B2 (ja) * 2014-09-25 2018-09-19 富士フイルム株式会社 プロポフォール含有水中油型エマルション組成物及びその製造方法
US20170224662A1 (en) * 2016-01-22 2017-08-10 The Medicines Company Aqueous Formulations and Methods of Preparation and Use Thereof
WO2017132243A1 (en) * 2016-01-29 2017-08-03 Cuda Anesthetics, Llc Aqueous pharmaceutical formulation comprising propofol
EP3567059A1 (en) * 2018-05-09 2019-11-13 Biocydex Substituted cyclodextrin-metal complexes and uses thereof
US20220000797A1 (en) * 2018-11-07 2022-01-06 (Bika Biotechnology (Guangzhou) Co., Ltd) Clear propofol injection and preparation method therefor
CN111150703A (zh) * 2018-11-07 2020-05-15 比卡生物科技（广州）有限公司 一种澄清丙泊酚注射液及其制备方法
US10973780B2 (en) * 2019-05-15 2021-04-13 Bexson Biomedical, Inc. Ketamine formulation for subcutaneous injection
US20230102590A1 (en) * 2020-02-03 2023-03-30 Senju Pharmaceutical Co., Ltd. Use of polyether compound
JP2023551145A (ja) 2020-11-18 2023-12-07 ベクソン バイオメディカル，インク． 医薬化合物の錯化剤塩製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
US6362234B1 (en) * 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane

Also Published As

Publication number Publication date
EP1383445A1 (en) 2004-01-28
JP2004526730A (ja) 2004-09-02
AU2002254309B2 (en) 2006-02-02
WO2002074200B1 (en) 2003-03-06
WO2002074200A1 (en) 2002-09-26
US20030055023A1 (en) 2003-03-20
EP1383445A4 (en) 2005-04-13
CA2441744A1 (en) 2002-09-26
JP4334229B2 (ja) 2009-09-30

Similar Documents

Publication Publication Date Title
CA2441744C (en) Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7034013B2 (en) Formulations containing propofol and a sulfoalkyl ether cyclodextrin
AU2002254309A1 (en) Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US12303519B2 (en) Injectable pharmaceutical compositions comprising a cyclodextrin a hydrophobic drug, a co-solvent, and a preservative
AU2003234285B2 (en) Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
JP6407221B2 (ja) 抗菌性組成物
US9907859B2 (en) ST-246 liquid formulations and methods
DK1713504T3 (en) Antimicrobial preservatives to obtain multi-dose formulations using beta-cyclodextrins for liquid dosage forms
JP2009504634A (ja) プロポフォールを含む水性麻酔剤組成物
HK1198325B (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone
NZ706101B2 (en) Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
NZ624592B2 (en) Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
MXPA06008032A (en) Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220321